MARKET

VRTX

VRTX

Vertex Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

284.82
-9.63
-3.27%
After Hours: 283.13 -1.7 -0.60% 17:14 07/13 EDT
OPEN
293.05
PREV CLOSE
294.45
HIGH
296.85
LOW
283.85
VOLUME
1.66M
TURNOVER
--
52 WEEK HIGH
306.08
52 WEEK LOW
165.23
MARKET CAP
73.85B
P/E (TTM)
49.43
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 26 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VRTX stock price target is 290.91 with a high estimate of 330.00 and a low estimate of 245.00.

EPS

VRTX News

More
3 Absolutely Rock-Solid Stocks to Buy Before the Market Crashes Again
Motley Fool · 1d ago
ClearBridge Aggressive Growth Strategy Portfolio Manager Commentary Q2 2020
Seeking Alpha - Article · 1d ago
Direxion launches three buy-and-hold ETFs for long-term investors with one focused on high growth
Direxion's new fund leverages growth, quality and momentum factors to give investors a high-growth offering that attempts to limit market downside.
CNBC.com · 2d ago
Vertex Pharmaceuticals (VRTX) Stock Moves -0.18%: What You Should Know
Zacks · 3d ago
Here's Why CRISPR Therapeutics Shares Jumped 13.8% in June
Motley Fool · 5d ago
Were Hedge Funds Right About Vertex Pharmaceuticals Incorporated (VRTX)?
Insider Monkey · 5d ago
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)
Benzinga · 5d ago
Morgan Stanley Downgrades Vertex Pharmaceuticals to Equal-Weight, Raises Price Target to $300
Morgan Stanley analyst Matthew Harrison downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Overweight to Equal-Weight and raises the price target from $277 to $300.
Benzinga · 5d ago

Industry

Biotechnology & Medical Research
-1.52%
Pharmaceuticals & Medical Research
+0.01%

Hot Stocks

Symbol
Price
%Change

About VRTX

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
More

Webull offers kinds of Vertex Pharmaceuticals Incorporated stock information, including NASDAQ:VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.